Abola Matthew V, Thompson Cheryl L, Chen Zhengyi, Chak Amitabh, Berger Nathan A, Kirwan John P, Li Li
Department of Family Medicine and Community Health, Research Division, Case Western Reserve University11001 Cedar Avenue, Suite 200, Cleveland, Ohio, 44016, USAEpidemiology and Biostatistics, Case Western Reserve University10900 Euclid Avenue, Cleveland, Ohio, 44106, USATransdisciplinary Research on Energetics and Cancer Program, Case Comprehensive Cancer Center, Case Western Reserve University and University Hospitals of Cleveland11100 Euclid Avenue, Cleveland, Ohio, 44106, USADepartment of Medicine, University Hospitals Case Medical Center11100 Euclid Avenue, Cleveland, Ohio, 44106, USADepartment of Pathobiology, Lerner Research InstituteCleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio, 44195, USA.
Department of Family Medicine and Community Health, Research Division, Case Western Reserve University11001 Cedar Avenue, Suite 200, Cleveland, Ohio, 44016, USAEpidemiology and Biostatistics, Case Western Reserve University10900 Euclid Avenue, Cleveland, Ohio, 44106, USATransdisciplinary Research on Energetics and Cancer Program, Case Comprehensive Cancer Center, Case Western Reserve University and University Hospitals of Cleveland11100 Euclid Avenue, Cleveland, Ohio, 44106, USADepartment of Medicine, University Hospitals Case Medical Center11100 Euclid Avenue, Cleveland, Ohio, 44106, USADepartment of Pathobiology, Lerner Research InstituteCleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio, 44195, USA Department of Family Medicine and Community Health, Research Division, Case Western Reserve University11001 Cedar Avenue, Suite 200, Cleveland, Ohio, 44016, USAEpidemiology and Biostatistics, Case Western Reserve University10900 Euclid Avenue, Cleveland, Ohio, 44106, USATransdisciplinary Research on Energetics and Cancer Program, Case Comprehensive Cancer Center, Case Western Reserve University and University Hospitals of Cleveland11100 Euclid Avenue, Cleveland, Ohio, 44106, USADepartment of Medicine, University Hospitals Case Medical Center11100 Euclid Avenue, Cleveland, Ohio, 44106, USADepartment of Pathobiology, Lerner Research InstituteCleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio, 44195, USA Department of Family Medicine and Community Health, Research Division, Case Western Reserve University11001 Cedar Avenue, Suite 200, Cleveland, Ohio, 44016, USAEpidemiology and Biostatistics, Case Western Reserve University10900 Euclid Avenue, Cleveland, Ohio, 44106, USATransdisciplinary Research on Energetics and Cancer Program, Case Comprehensive Cancer Center, Case Western Reserve University and University Hospitals of Cleveland11100 Euclid Avenue, Cleveland, Ohio, 44106, USADepartment of Medicine, University Hospitals Case Medical Center11100 Euclid Avenue, Clev
Endocr Relat Cancer. 2015 Apr;22(2):L1-4. doi: 10.1530/ERC-14-0429.
Retinol binding-protein 4 (RBP4), a recently identified adipokine and retinol transporter, has been shown to play a causative role in insulin resistance, an underpinning between obesity and colon neoplasia. Yet, the relationship between RPB4 and cancer, including colon neoplasia is largely unexplored. We carried out a cross-sectional study to determine the risk association between RBP4 and colon adenomas. We determined pre-diagnostic serum levels of RBP4 in 626 patients undergoing screening colonoscopies from January 2006 to March 2007. The cases had statistically significant higher levels of RBP4 than the controls (58.5µg/mL ± 38.2 vs. 51.9µg/mL ± 32.5, p=0.03). Multivariate logistic regression model revealed a statistically significant overall association of RBP4 with risk of colon adenoma (OR = 3.10 for each increment of 35µg/mL, CI = 1.15 – 8.66; p = 0.03). Stratified analysis by the median BMI showed that the risk association was largely limited to those with BMI < 27.8 kg/m. Compared to those in the bottom tertile of RBP4, the ORs for the 2 and 3 tertiles were 1.84 (CI = 0.89–3.8) and 2.14 (CI = 1.08–4.23) respectively (p for trend = 0.03); there was little evidence for such an association among those with BMI ≥ 27.8 kg/m. This is the first study to show colon adenoma risk association with high circulating levels of RBP4. Further study is merited to investigate the mechanism that underlies the RBP4-colon neoplasia link.
视黄醇结合蛋白4（RBP4）是一种最近发现的脂肪因子和视黄醇转运蛋白，已被证明在胰岛素抵抗中起致病作用，而胰岛素抵抗是肥胖与结肠肿瘤形成之间的一个基础环节。然而，RPB4与癌症（包括结肠肿瘤）之间的关系在很大程度上尚未得到探索。我们开展了一项横断面研究，以确定RBP4与结肠腺瘤之间的风险关联。我们测定了2006年1月至2007年3月期间接受结肠镜筛查的626例患者诊断前血清RBP4水平。病例组的RBP4水平在统计学上显著高于对照组（58.5μg/mL±38.2 vs. 51.9μg/mL±32.5，p = 0.03）。多因素逻辑回归模型显示，RBP4与结肠腺瘤风险存在统计学上显著的总体关联（每增加35μg/mL，OR = 3.10，CI = 1.15 - 8.66；p = 0.03）。按BMI中位数进行分层分析表明，风险关联主要限于BMI < 27.8 kg/m的人群。与RBP4处于最低三分位数的人群相比，第二和第三三分位数人群的OR分别为1.84（CI = 0.89 - 3.8）和2.14（CI = 1.08 - 4.23）（趋势p = 0.03）；在BMI≥27.8 kg/m的人群中几乎没有这种关联的证据。这是第一项显示循环中RBP4水平升高与结肠腺瘤风险相关的研究。值得进一步研究以探讨RBP4与结肠肿瘤形成之间联系的潜在机制。
